Ascertaining Diagnosis Classification With Elicited Speech
NCT ID: NCT05601063
Last Updated: 2022-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
255 participants
OBSERVATIONAL
2020-10-01
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Linguistic Predictors of Outcomes in Psychosis
NCT05601050
Predicting Psychotic Relapse Using Speech-Based Early Detection
NCT06978894
Neural Correlates of Social Touch and Interoceptive Perception As Potential Biomarker for Impaired Social Functioning
NCT04968223
Study of Language Disorders and Interactions Between Mnesic Capabilities and Semantic Competencies in Patients With Psychosis
NCT06036316
Semantic and Syntactic Computerized Analysis of Free Speech
NCT03525054
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Psychiatric patient group
Current diagnosis in the medical chart of any of the following. The patient may be in partial but not full remission. Comorbidity among these disorders and other unlisted disorders is expected and allowable.
* Schizophrenia-spectrum disorder - schizophrenia, schizophreniform, schizoaffective disorder, delusional disorder, brief psychotic disorder, or unspecified psychotic disorder
* Bipolar spectrum disorder - bipolar I or II disorder, cyclothymia, unspecified or other specified bipolar disorder
* (Unipolar) Depressive disorder - major depressive disorder, dysthymia, unspecified and other specified depressive disorder
* Anxiety disorder - obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, post-traumatic stress disorder
* Personality disorder - borderline personality disorder
* Attention-Deficit Hyperactivity Disorder
Winterlight Speech Assessment
Digital assessment of speech and language abilities
Healthy controls
Healthy comparison subjects with no known psychiatric diagnosis
Winterlight Speech Assessment
Digital assessment of speech and language abilities
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Winterlight Speech Assessment
Digital assessment of speech and language abilities
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current diagnosis in the medical chart of any of the following. The patient may be in partial but not full remission. Comorbidity among these disorders and other unlisted disorders is expected and allowable.
* Schizophrenia-spectrum disorder - schizophrenia, schizophreniform, schizoaffective disorder, delusional disorder, brief psychotic disorder, or unspecified psychotic disorder
* Bipolar spectrum disorder - bipolar I or II disorder, cyclothymia, unspecified or other specified bipolar disorder
* (Unipolar) Depressive disorder - major depressive disorder, dysthymia, unspecified and other specified depressive disorder
* Anxiety disorder - obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, post-traumatic stress disorder
* Personality disorder - borderline personality disorder
* Attention-Deficit Hyperactivity Disorder
* Healthy comparison subjects
* Age 14 - 50 years
* Has capacity and willing to sign informed consent; if minor, parent is willing to give consent and child is willing to give assent.
* Screening will not include a pregnancy test. Pregnant women will not be screened out of the study because the study procedures are of very low risk overall, and pregnancy does not place the participant or the fetus at any significant risk.
* Minors will be included in the study because diagnostic ambiguity is prevalent before the age of 18 and this patient group is particularly in need of accurate prognosis and treatment. Therefore, it is of vital importance that the conclusions of the study be applicable to minors and that they be included among the participants.
Exclusion Criteria
* Disorders affecting speech or language, such as aphasia, intellectual disability (IQ\<70), or language disorder, or movement disorders affecting speech like tardive dyskinesia, or physical impairments causing significant distortions to speech
* Serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain and/or language, including but not limited to: neurodegenerative disorders, traumatic brain injury with active symptoms, autism spectrum disorder, encephalitis, epilepsy
* Cognitive or language limitations, or any other factor that would preclude subjects providing informed consent
14 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Winterlight Labs
INDUSTRY
Northwell Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sunny Tang
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sunny X Tang, MD
Role: PRINCIPAL_INVESTIGATOR
Northwell Health, The Feinstein Institutes of Medical Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zucker Hillside Hospital
Glen Oaks, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-0468
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.